Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

June 23, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
Gastric AdenocarcinomaEsophagus AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Trifluridine/Tipiracil

Trifluridine/Tipiracil will be administered with a 14-day schedule (35 mg/m² BID for 5 days followed by 9 days of recovery) until disease progression or intolerable toxicity.

DRUG

Oxaliplatin

Oxaliplatin will be administered intravenously on day 1 of each treatment cycle (infusion duration: 2 hours), every 2 weeks. The first cycle will be administered at level -1 (70 mg/m²) and then increased to 85 mg/m² (if feasible) from the cycle 2 to 8 or until disease progression, whatever occurs first. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and Trifluridine/Tipiracil will be continued alone until disease progression or intolerable toxicity.

DRUG

FOLFOX regimen

Folinic Acid 400 mg/m² (or 200 mg/m² if L-folinic acid) + oxaliplatin 85 mg/m² (infusion duration: 2 hours) followed by 5-FU bolus 400 mg/m² and then 5-FU 2400 mg/m² as a 46-hour continuous infusion. Treatment repeated every 14 days. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and 5-FU (simplified LV5FU2 regimen) or capecitabine (1000 mg/m² BID during 2 weeks every 3 weeks) will be continued alone until disease progression or intolerable toxicity.

DRUG

Nivolumab

Nivolumab 240 mg (infusion duration 30 minutes, every 2 weeks) until disease progression or intolerable toxicity for a maximum of 2 years

Trial Locations (29)

13008

RECRUITING

Hôpital Saint Joseph, Marseille

13009

RECRUITING

Institut Paoli Calmettes, Marseille

21079

WITHDRAWN

Centre Georges François Leclerc, Dijon

25030

RECRUITING

CHU Besançon - Hôpital Jean Minjoz, Besançon

25250

RECRUITING

Hôpital Nord Franche Comté, Montbéliard

29200

RECRUITING

CHU Morvan, Brest

NOT_YET_RECRUITING

Clinique Pasteur Lanroze, Brest

44805

RECRUITING

ICO - Site René Gauducheau, Saint-Herblain

49000

RECRUITING

CH Cholet, Cholet

51092

RECRUITING

CHU - Hôpital Robert Debré, Reims

51100

RECRUITING

Institut Jean Godinot, Reims

54500

RECRUITING

CHU Nancy - Hôpital Brabois, Vandœuvre-lès-Nancy

59210

RECRUITING

Institut Andrée Dutreix - Clinique de Flandre, Coudekerque-Branche

60021

RECRUITING

Centre Hospitalier de Beauvais, Beauvais

62000

RECRUITING

Hopital Privé Arras Les Bonnettes, Arras

63011

RECRUITING

Centre Jean Perrin, Clermont-Ferrand

63100

RECRUITING

CHU d'Estaing, Clermont-Ferrand

67033

RECRUITING

Institut de cancérologie Strasbourg Europe, Strasbourg

69373

RECRUITING

Centre Léon Bérard, Lyon

69400

RECRUITING

Hôpital Nord-Ouest Villefranche-sur-Saône, Gleizé

75010

RECRUITING

Hôpital Saint Louis, Paris

75015

RECRUITING

Hopital Europeen Georges Pompidou, Paris

75020

RECRUITING

GH Diaconesses - Crois St Simon, Paris

75674

RECRUITING

Institut Mutualiste Montsouris, Paris

76000

RECRUITING

CHU Rouen - Charles Nicolle, Rouen

80000

NOT_YET_RECRUITING

Clinique de l'Europe, Amiens

84000

RECRUITING

Institut Sainte Catherine, Avignon

86000

RECRUITING

CHU de Poitiers, Poitiers

06189

RECRUITING

Centre Antoine Lacassagne, Nice

All Listed Sponsors
collaborator

Servier

INDUSTRY

lead

UNICANCER

OTHER